Engineering Technologies and Clinical Translation
Volume 3 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
- 1st Edition - August 25, 2021
- Imprint: Academic Press
- Editors: Mansoor M. Amiji, Lara Scheherazade Milane
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 0 9 4 9 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 9 5 0 - 1
Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of deliverin… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteEngineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies, focusing specifically on the development of solutions for drug delivery and its clinical outcomes. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses biomaterial, microfluidic, and biodegradable devices, engineered microbes, personalized medicine, clinical approval process, and many other IO technologies.
Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.
- Explores engineering technologies and their clinical translation in a comprehensive way
- Presents forecasting on the future of nanotechnology and drug delivery for IO
- Engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side
Scientists and clinicians working in research and development of IO therapeutics and vaccines. Graduate students and postdoctoral associate working in this field
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Acknowledgments
- Chapter One: Engineering solutions to design CAR-T cells
- Abstract
- 1: Introduction
- 2: Pharmacological aspects of CAR-T cells
- 3: What can be engineered in CAR T-cells?
- 4: Gene delivery to engineer CAR-T cells
- 5: Universal/SUPRA CAR-T cells
- 6: Critical aspects for clinical development
- 7: Conclusion
- Chapter Two: Engineered microbes for cancer immunotherapy
- Abstract
- 1: Microbes as tumor immunotherapy
- 2: Application of synthetic biology to therapeutics
- 3: Synthetic biology techniques to engineer safety and control growth
- 4: Application of synthetic biology to engineer microbial therapeutics for cancer
- 5: Regulatory considerations in the development of engineered bacteria as therapeutics
- 6: Conclusion
- Chapter Three: Polymeric scaffolds for antitumor immune cell priming
- Abstract
- 1: Introduction
- 2: Polymeric materials and scaffold systems
- 3: Polymeric scaffolds for DC priming and activation
- 4: Polymeric scaffolds for T-cell activation
- 5: Conclusion and future perspectives
- Chapter Four: Biomaterials and devices for immunotherapy
- Abstract
- 1: Introduction
- 2: Immunotherapy and chemotherapy combinations
- 3: Nanoscale biomaterial-based strategies applied
- 4: Introduction to micro/nanorobots
- 5: Propulsion engines for MNRs
- 6: Applications of MNRs
- 7: Conclusion and future outlook
- Chapter Five: Engineered devices for tumor microenvironment immune modulation
- Abstract
- 1: Introduction
- 2: Local delivery of engineered devices for tumor immune modulation
- 3: Transdermal delivery of engineered devices for tumor immune modulation
- 4: Systemic delivery of engineered devices for tumor immune modulation
- 5: Limitations, perspectives and future work
- Chapter Six: Tumor-on-a-chip devices for cancer immunotherapy
- Abstract
- 1: Introduction
- 2: Microfluidics
- 3: Recapitulating the tumor microenvironment
- 4: Predicating therapeutic efficacy
- 5: Production of therapeutic cells
- 6: Screening immune cells
- 7: Conclusion
- Chapter Seven: Challenges and opportunities of nanotechnology in cancer immunotherapy
- Abstract
- 1: Background in cancer immunotherapy
- 2: Immunogenic cell death with nanotechnology
- 3: Vaccination with nanotechnology
- 4: Activation of innate immunity
- 5: T cell activation
- 6: Targeting strategies
- 7: Perspective
- Chapter Eight: Stromal modulation strategies to improve immunotherapy response in cancer
- Abstract
- Acknowledgments
- 1: Background
- 2: Tumor stroma mediated immunosuppression
- 3: Stromal modulation strategies with nanotechnology to improve immunotherapy
- 4: Conclusions
- Chapter Nine: Spatial mapping of the tumor immune microenvironment
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Conventional tissue preparation and processing for cancer histology
- 3: Mapping proteins and transcripts in the TIME
- 4: Spatial 'omics
- 5: Conclusions and future prospects
- Chapter Ten: Nucleic acid biomarker technology for cancer immunotherapy
- Abstract
- Acknowledgment
- 1: Introduction
- 2: NGS and cancer
- 3: Transcriptional signatures
- 4: Single cell
- 5: CRISPR based
- 6: Current challenges in immunogenomics
- 7: Conclusion
- Chapter Eleven: Proteomic biomarker technology for cancer immunotherapy
- Abstract
- 1: Introduction and background
- 2: Proteomic technologies
- 3: Proteomic analysis of immune-related adverse events
- 4: Discussion and future directions
- Chapter Twelve: Personalized cancer immunotherapy
- Abstract
- 1: Part I. Identifying immune checkpoint blockade therapy-responsive patients
- 2: Biomarkers based on tumor “foreignness”
- 3: Tumor immune microenvironment and immunotherapy response
- 4: “Omics” technologies in personalized immunooncology
- 5: Immunotherapy response biomarkers not directly measured in tumor
- 6: Integrating biomarkers to reach “precision” and tailor therapy to patient's unique immunome
- 7: Part II. Highly personalized immunotherapy
- 8: Adoptive T cell transfer: A highly personalized therapy for human cancers
- 9: Tumor-infiltrating lymphocytes: A rich source of tumor specific T cells
- 10: Tumor neoantigens and their role in tumor immunity
- 11: Neoantigen reactive T cells; broadening the landscape of personalized cancer immunotherapies
- 12: Neoantigen vaccines
- 13: Neoantigen-specific T cells for adoptive cellular therapies
- 14: Concluding remarks
- Chapter Thirteen: Image-guided cancer immunotherapy
- Abstract
- 1: Introduction
- 2: Clinically relevant imaging modalities to assess anatomic and functional tumor response
- 3: Imaging approaches to probe the immune system
- 4: Imaging targets for immunotherapy
- 5: Imaging of other immune targets
- 6: Imaging immune cellular subsets
- 7: Imaging to guide bispecific T-cell engager therapy (BiTE)
- 8: Image-guided interventional immunotherapies
- 9: Summary and future directions
- Chapter Fourteen: Clinical translation and challenges in cancer immunotherapies
- Abstract
- 1: Introduction
- 2: Challenges in developing cancer immunotherapies
- 3: Drug development considerations for clinical translation
- 4: Conclusion
- Index
- Edition: 1
- Published: August 25, 2021
- No. of pages (Paperback): 524
- No. of pages (eBook): 524
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780323909495
- eBook ISBN: 9780323909501
MA
Mansoor M. Amiji
Mansoor M. Amiji is the Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences at the Bouvé College of Health Sciences at Northeastern University. Dr. Amiji has edited a number of books and is a frequently published author. His research focuses on the synthesis of novel polymeric materials for medical and pharmaceutical applications, drug delivery systems and nanomedical technologies, and his contributions in research advising, grant reviews for various organizations and editorial work for journals are invaluable.
Affiliations and expertise
Distinguished Professor and Chairman, Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts, USALM
Lara Scheherazade Milane
Dr. Lara Milane is Assistant Teaching Professor in Biotechnology at the Bouvé College of Health Sciences at Northeastern University. She is interested in Mitochondrial Medicine. She is working on developing nanomedicines for a range of diseases (cancer, neurodegenerative disease, aging) that manipulate mitochondria for therapeutic outcomes. Dr. Milane was trained as a National Cancer Institute/ National Science Foundation Nanomedicine Fellow at Northeastern University, Boston, MA. Dr. Milane is an intuitive cancer biologist with research interests in developing translational nanomedicines that exploit the hallmarks of cancer.
Affiliations and expertise
Assistant Teaching Professor in Biotechnology, Bouve College of Health Sciences, Northeastern University, USARead Engineering Technologies and Clinical Translation on ScienceDirect